Arbutus Biopharma Co. (NASDAQ: ABUS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna
Arbutus Biopharma Co. (NASDAQ: ABUS) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Early Warning Report Issued Pursuant to National Instrument 62-103: Roivant announces Resignation and Replacement of Arbutus Board [Yahoo! Finance]